Not available
Quote | Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Last: | $1.39 |
---|---|
Change Percent: | 0.0% |
Open: | $1.3 |
Close: | $1.39 |
High: | $1.42 |
Low: | $1.295 |
Volume: | 1,926,163 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Adaptimmune Therapeutics plc (NASDAQ:ADAP)
2024-07-03 11:11:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips For most of the year, biotech has been one of the most explosive sectors on the market. Far from over, further upside is likely, thanks to some of the top biotech stocks with catalysts. ...
2024-07-03 09:54:32 ET Summary Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ...
Message Board Posts | Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Subject | By | Source | When |
---|---|---|---|
ASCO The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly | jondoeuk | investorshub | 04/30/2023 5:33:59 PM |
From FB https://www.fiercepharma.com/pharma/astellas-writes-340m-fibrogens-evren | jondoeuk | investorshub | 04/14/2023 1:08:05 AM |
The company said it will regain rights to | jondoeuk | investorshub | 04/11/2023 6:54:34 PM |
Upcoming https://annualmeeting.asgct.org/program/agenda-details?agendaId=26880 | jondoeuk | investorshub | 04/10/2023 5:52:14 PM |
(OT) Two interesting preclinical papers https://jitc.bmj.com/content/11/4/e00551 | jondoeuk | investorshub | 04/05/2023 8:56:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma pa...
2024-05-31 16:15:02 ET Wells Fargo analyst issues EQUAL-WEIGHT recommendation for ADAP on May 31, 2024 02:43PM ET. The previous analyst recommendation was Equal-Weight. ADAP was trading at $1.135 at issue of the analyst recommendation. The overall analyst consensus : BUY...